[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Bordeaux\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":716},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,167,0,25,[9,48,82,109,150,178,199,224,258,282,312,340,368,396,419,448,476,500,522,553,573,605,637,663,691],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644894","sage-heart--senior-assessment-fragility-and-post-operative-qalys-1-year-after-emergency-heart-surgery-for-patients-aged-75-and-older-100644894",false,"NCT07677319","SAGE-Heart : Senior Assessment fraGility and Post-opErative QALYs 1 Year After Emergency HEART Surgery for Patients Aged 75 and Older","SAGE-Heart","Inclusion Criteria:\n\n* Patients aged ≥ 75 years who are affiliated with or beneficiaries of a social security scheme and undergoing emergency cardiac surgery under cardiopulmonary bypass, either immediate or urgent (relative) :\n\n  * Immediate emergency surgery: intervention performed before the start of the next working day following the decision to operate,\n  * Urgent (relative) emergency surgery: patients not admitted electively for surgery but requiring an intervention during the current hospital stay for medical reasons, and who cannot be discharged without undergoing a definitive procedure\n\nExclusion Criteria:\n\n* Patients requiring preoperative cardiopulmonary resuscitation\n* Scheduled (elective) surgery\n* Lack of informed consent\n* Impaired consciousness at the time of inclusion (defined by a Glasgow Coma Scale score \\\u003C 15)\n* Individuals under legal guardianship or judicial protection\n* Individuals participating in another interventional research protocol","ALL","75 Years",{"count":20,"type":21},265,"ESTIMATED","INTERVENTIONAL",[24],"NA","The hypothesis is that the preoperative Clinical Frailty Score (CFS) is a predictive factor for a loss in quality-adjusted life years (QALYs) one year after emergency cardiac surgery under cardiopulmonary bypass (CPB) in patients aged 75 years and older.",[27,28,29],"Frailty","Cardiac Surgery","QALYs",[27,31,28,32,29,33,34],"Elderly","Cardio-pulmonary Bypass","Clinical Frailty Scale","EuroQol, postoperative","RECRUITING","2026-06-29",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"2025-12-03",{"date":43,"type":21},"2028-12-03",{"name":45,"class":46},"University Hospital, Bordeaux","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100645085","model-early-immunologic-stages-of-pediatric-hematological-pre-lupus-100645085","NCT07680010","Model Early Immunologic Stages of Pediatric Hematological Pre-lupus","Model Early Immunologic Stages of Pediatric Hematological Pre-lupus in Order to Prevent SLE in Children.","PRELUDE","* Inclusion criteria:\n\n  * For patients :\n\n    * Child or adolescent with newly diagnosed ITP or SLE according to the specific definitions of ITP or SLE, prior to any treatment,\n    * Over 1 and under 18 years of age at diagnosis, weighing more than 7 kg.\n    * Written consent from parents or guardians,\n    * Patient affiliated to a social security scheme.\n  * For controls :\n\n    * Over 1 and under 18 years of age at diagnosis, weighing more than 7 kg.\n    * Follow-up in the day hospital at the Bordeaux University Hospital, for a condition that does not affect the immune system\n    * Matched on age,\n    * Written consent from parents or guardians,\n    * Patient affiliated to a social security scheme\n* Exclusion criteria:\n\n  * For patients :\n\n    * ITP secondary to a known cause: previous or concomitant immune deficiency, bone marrow or organ transplantation, other autoimmune disease, Evans syndrome (autoimmune hemolytic anemia or autoimmune neutropenia present at ITP diagnosis) or cancer with immunosuppressive therapy.\n    * Treatment with immunomodulation or immunosuppressants (including immunoglobulins, corticoids, hydroxychloroquine), started prior to inclusion (day of sampling).\n    * Pregnant women, women in labour and breastfeeding women\n  * For controls :\n\n    * Suffering from an immunological disease,\n    * Infection within fifteen days prior to inclusion,\n    * Immunomodulatory therapy.\n    * Pregnant women, women in labour and breastfeeding women",true,"1 Year","18 Years",{"count":60,"type":21},105,[24],"Immunologic thrombocytopenic purpura (ITP) in children is a pre-lupus condition if associated with the presence of anti-nuclear antibodies (ANA), providing a unique model for understanding the natural history of autoimmunity, particularly that of systemic lupus erythematosus (SLE). We will describe the shared and\u002For unique immunological pathways involved at diagnosis in 70 children with ITP and in 20 children with SLE, and compare them between ITP-ANA- (more often transient), ITP-ANA+ (pre-lupus condition, more often persistent) and SLE",[64,65],"Immune Thrombocytopenic Purpura ( ITP )","Systemic Lupus Erythematosus (SLE)",[67,68,69,70,71],"Children","Immunologic Thrombocytopenic Purpura","Anti-Nuclear Antibody","Systemic Lupus Erythematosus","Biomarkers","NOT_YET_RECRUITING","2026-06-25",{"date":75,"type":39},"2026-07-01",{"date":77,"type":21},"2026-07",{"date":79,"type":21},"2033-10",{"name":45,"class":46},2,{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100308304","uroccr-database-french-research-network-for-kidney-cancer--uroccr-100308304","NCT03293563","UroCCR Database: French Research Network for Kidney Cancer -UroCCR","UroCCR Database: French Research Network for Kidney Cancer (National Multidisciplinary Clinical and Biological Database on Kidney Cancer)","UroCCR","Inclusion Criteria:\n\n* Adult patient with kidney cancer\n* Patient with no opposition to collection of its data for the study\n\nExclusion Criteria: none",{"count":91,"type":21},30000,"OBSERVATIONAL","Kidney cancer management has become increasingly complex with the diversification of treatment options and the integration of multidisciplinary care. To meet these challenges, the UroCCR network was established in France as a national registry and research platform dedicated to renal cancer. Funded by the French National Cancer Institute (INCa), UroCCR prospectively collects comprehensive real-world data on patient care and disease evolution, while systematically linking these records with annotated biological samples (plasma, urine, and both healthy and tumour tissues). For each case, more than one thousand variables may be recorded, covering clinical, imaging, and patient-reported information.\n\nMore than a registry, UroCCR is a collaborative network of clinical and research professionals using a shared, evolving tool that supports rapid implementation of studies and fosters active knowledge generation. Unlike retrospective registries or sample-centred biobanks, UroCCR offers prospective, patient-focused inclusion and a wide scope of investigation-from translational and technological research to clinical evaluation and social sciences. It also supports multiple ancillary studies, including retrospective analyses and prospective clinical or observational trials, and operates under a structured governance system with recognised national and international labels.\n\nBy combining a rigorously structured, multicentre dataset with linkage to the French national health data system (SNDS), the platform uniquely unites detailed clinical annotation with population-wide coverage, creating a high-value environment for advancing kidney cancer research and care.",[95],"Kidney Cancer",[97,98,99,100],"Kidney cancer","Surgical approaches","Medical treatment","Multicentric and multidisciplinary network","2026-06-22",{"date":73,"type":39},{"date":104,"type":4},"2011-12",{"date":106,"type":21},"2040-12",{"name":45,"class":46},68,{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":56,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":131,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":47},"100644109","morphology-in-oral-rare-syndromes--artificial-intelligence-for-clinical-diagnosis-100644109","NCT07666269","Morphology in Oral Rare Syndromes & Artificial Intelligence for Clinical Diagnosis","Geometric Morphometric Characterization of Oro-Dental Anomalies in Rare Bone and Cartilage Diseases From 3D Digital Data (MOSAIC)","MOSAIC","Inclusion Criteria:\n\n* For cases: Diagnosis of a rare bone and cartilage disorder confirmed by the Rare Disease Competence Center for Constitutional Bone Disorders (MOC) or Calcium and Phosphate Metabolism Disorders (CaP), genetically and\u002For clinically.\n* Ability to undergo a 3D intra-oral scan;\n* Ability of the participant to understand the information notice provided regarding the use of their medical data and 3D digital models for research purposes, and to express informed non-objection to participation in the research.\n* For controls: healthy adults recruited in the Dental Medicine Department.\n\nExclusion Criteria:\n\n* History of major orthodontic\u002Forthognathic treatment;\n* Craniofacial conditions unrelated to the studied diseases (e.g., cleft palate, non-target craniofacial syndromes);\n* Impossibility to obtain a 3D optical impression;\n* Refusal or inability of the participant to understand the information notice and\u002For to express informed non-objection to participation in the research.",{"count":118,"type":21},240,[24],"MOSAIC aims to determine whether oro-dental morphological anomalies, particularly palatal morphology, associated with rare bone and cartilage diseases can be precisely characterized using 3D digital models analysed through geometric morphometrics. The study will also evaluate whether these morphological signatures can train an artificial intelligence (AI) algorithm to classify syndromes. A prospective monocentric case-control cohort will be constituted, including 3D intra-oral scans and associated clinical data. The final goal is to improve diagnostic accuracy and reduce diagnostic delay in rare bone disorders.",[122,123,124,125,126,127,128,129,130],"Osteogenesis Imperfecta","Rare Bone Disorders","Hypophosphatemia","X-Linked","Mucopolysaccharidoses","Tooth Abnormalities","Palate; Deformity","Artificial Intelligence (AI)","Machine Learning",[132,133,134,135,136,137,138,139,140,141],"Rare bone diseases","palatal morphology","geometric morphometrics","3D intra-oral scan","machine learning","artificial intelligence","diagnostic classification","osteogenesis imperfecta","X-linked hypophosphatemia","mucopolysaccharidosis","2026-06-18",{"date":144,"type":39},"2026-06-24",{"date":146,"type":21},"2026-09-01",{"date":148,"type":21},"2028-03-01",{"name":45,"class":46},{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":56,"sex":17,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":81},"100644164","advancing-neurogenetic-diagnoses-through-long-read-sequencing-100644164","NCT07665554","Advancing Neurogenetic Diagnoses Through Long-Read Sequencing","NRGEN-NGS3 : Advancing Neurogenetic Diagnoses Through Long-Read Sequencing","NRGEN-NGS3","Inclusion Criteria:\n\n* All participants :\n\n  * Participants affiliated with or beneficiaries of a social security scheme\n  * Participants who speak French\n  * Participants aged ≥ 6 and ≤ 60 years\n* For patients requiring a new sample:\n\n  * Free and informed consent, signed by the parents or the holder of parental authority for patients under the age of 18\n  * Free and informed consent, signed by the patient's representative for adults under guardianship\n  * Free and informed consent, signed by the adult patient\n* For diagnosed patients :\n\n  • DeoxyriboNucleic Acid (DNA) sample from a subject carrying a nucleotide repeat expansion in one of the selected genes.\n  * DNA available in sufficient quantity (5-10 µg) or patient agreeing to a blood draw from which DNA will be extracted.\n  * DNA extraction methods known and validated by the steering committee (see paragraph 7).\n* For participants from undiagnosed families :\n\n  o Index cases:\n\n  • Patient affected by a neurological disease candidate for these repeats, for which genomic data did not reveal mutations or expansions in known genes.\n  * Patient whose DNA is already available and whose extraction method is known and validated by the steering committee or patient whose DNA is not available but who agrees to a blood draw.\n  * Patient willing to undergo a skin biopsy if not previously obtained.\n  * Patient with no family members affected by any of the neurological diseases candidate for these repeats, i.e., genomic data do not reveal mutations or expansions in known genes.\n  * Patient from a family in which at least one affected and one unaffected member agree to partici-pate in the study by providing a sample, or whose DNA is already available and extracted using a method known and validated by the steering committee.\n\n    * For all related members of undiagnosed families who have agreed to participate:\n  * Have at least two other family members who have agreed to participate in the study.\n  * Agree to provide a blood sample or have DNA already available in sufficient quantity and extracted using a method known and validated by the steering committee.\n  * Patient willing to undergo a skin biopsy if not previously obtained.\n  * Be affected by a neurological disease candidate for these repeats, for which genomic data did not reveal mutations or expansions in known genes, or be unaffected and have had a neurological examination showing no signs related to any of the neurological diseases candidate for these repeats.\n* For controls :\n\nParticipant for whom:\n\n* a consultation is scheduled at CHU Bordeaux for a reason other than a neurological disorder, has agreed to a neurological examination showing no signs of neurological disease, and has agreed to a blood draw and skin biopsy, or\n* the samples required for the study are already available in sufficient quantity in the CHU Bordeaux biobank and extracted using a method known and validated by the steering committee, or\n* accompanying a patient attending a consultation at CHU Bordeaux, showing no signs of neurologi-cal disease, and agreeing to a blood draw and skin biopsy, or whose samples are already available in sufficient quantity and extracted using a method known and validated by the steering committee.\n\nExclusion Criteria:\n\nFor all participants:\n\n• Refusal to participate in research: Refusal to provide informed consent or opposition to the use of these samples.\n\n* By the parents or the holder of parental authority for patients under the age of 18\n* By the patient's representative for adults under guardianship\n* By the adult patient This opposition from the patient must be communicated to the site investigator within a maximum of one month after the information note has been sent. If the letter confirming consent is returned due to an incorrect address, the patient will not be included.\n\n  * Degraded DNA or average size \\\u003C 30 kb","6 Years","60 Years",{"count":161,"type":21},304,[24],"Nucleotide repeats emerge as one of the most prolific classes of genetic variations. They have the propensity to in-crease in length across generations, and have been implicated in at least 65 known neurological\u002F neurodevelop-mental and neuromuscular conditions. Simultaneous analysis of all these nucleotide repeats is now possible through the cutting-edge methodologies recently developed that are the long-read sequencing and the optical genome mapping. Investigator propose to test these methodologies in patients carrying expansions in those repeats and to determine the capacity of these technics to detect novel repeats in patients with no genetic diagnosis yet.",[165],"Neurogenetic Diseases",[167,168,169,170,171],"long read sequencing","genetic diagnosis","cytogenetics","nucletotide repeat expansion","neurogenetic disease",{"date":144,"type":39},{"date":174,"type":21},"2026-09",{"date":176,"type":21},"2028-09",{"name":45,"class":46},{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":196,"leadSponsor":198,"locationsCount":47},"100644207","jugular-gating-for-upright-level-adjustment-and-targeted-enhancement-of-cerebral-perfusion-100644207","NCT07665606","JUgular Gating for Upright Level Adjustment and Targeted Enhancement of Cerebral Perfusion","JUGULATE","Inclusion Criteria:\n\n* Patients ≥ 18 years old\n* Hospitalized in the neurocritical care unit or the trauma unit\n* Scheduled for nursing care requiring a supine position.\n* Arterial catheter allowing continuous measurement of mean arterial pressure.\n* Central venous catheter for continuous measurement of central venous pressure.\n* External ventricular drain or intracranial pressure sensor for intracranial pressure monitoring.\n* Bed with controlled inclination capability.\n* Clinically stable condition allowing transient positional changes (as judged by the clinician).\n* Not included, or planned to be included in another trial.\n\nExclusion Criteria:\n\n* Contraindication to trunk mobilization.\n* Being a minor or placed under supervision.\n* Hemodynamic or respiratory instability.\n* Uncontrolled intracranial hypertension, refractory arterial hypertension, or severe dysautonomia.\n* Pregnancy or breastfeeding.\n* Refusal to participate in the study.",{"count":186,"type":21},30,"Investigators aim to demonstrate that the evolution of intracranial pressure (ICP) is nonlinear and may be influenced by jugular vein collapse. This collapse is estimated to occur at the angle where the hydrostatic pressure of the blood column matches the central venous pressure, and it can be assessed using ultrasonography. This approach allows for the determination of an individualized tilt angle, optimizing cerebral perfusion pressure without compromising venous drainage.",[189,190],"Intracranial Pressure","Critical Care",[189,192,193],"jugular vein collapse","Critical care",{"date":144,"type":39},{"date":146,"type":21},{"date":197,"type":21},"2027-03-31",{"name":45,"class":46},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":17,"minAge":158,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":223},"100511313","intestine-lung-axis-of-cystic-fibrosis-patients-treated-with-the-combination-elexacaftortezacaftorivacaftor-100511313","NCT05937815","Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor\u002FTezacaftor\u002FIvacaftor","Monitoring of the Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor\u002FTezacaftor\u002FIvacaftor: Study of the Pulmonary and Gut Microbiota and Inflammation","KAF-BIOTA","Inclusion Criteria:\n\n* To have cystic fibrosis (sweat test \\> 60 mmol\u002Fl);\n* Carrier of at least one DeltaF508 mutation;\n* Be followed in the current care by a participant in the CRCM study;\n* Start treatment with elexacaftor\u002Ftezacaftor\u002Fivacaftor in routine care, according to the indications in the Marketing Authorization at the time of inclusion;\n* Be of the age specified in the marketing authorization in force;\n* Person affiliated or beneficiary of a social security scheme;\n* Consent obtained by the patient (for adult patients) or the holders of parental authority (for minor patients) before any examination required by the research and oral and\u002For written consent by the participant (depending on his or her age) .\n* Patient agreeing to take part in cohort follow-up studies of patients treated with elexacaftor\u002Ftezacaftor\u002Fivacaftor, included in the French cystic fibrosis register (cf. Study by Pr BURGEL and\u002For MODUL CF).\n\nExclusion Criteria:\n\n* Start of treatment with elexacaftor\u002Ftezacaftor\u002Fivacaftor as part of a therapeutic trial.\n* Patient already on CFTR modulator (including lumacaftor\u002Fivacaftor)\n* Vulnerable people (pregnant woman, person under guardianship\u002Fcurators)","17 Years",{"count":209,"type":21},253,[24],"Cystic fibrosis is a systemic disease, which affects in particular the respiratory and digestive systems of patients, sites of chronic inflammation.\n\nA new combination of elexacaftor\u002Ftezacaftor\u002Fivacaftor has proven its efficacy for the treatment of patients aged 12 years and over with two F508del mutations or a so-called \"minimal function\" mutation associated with one F508del mutation. European marketing authorization was obtained in August 2020 and access in France should therefore arrive soon. Given that this treatment targets new mutations and that the efficacy seems greater than with LUM\u002FIVA, it is important to assess its impact on the microbiota and the pulmonary and digestive inflammation of patients.\n\nIt is therefore a question of taking advantage of the experience of the Lum-Iva-Biota cohort, and the validated and operational sample circuit established in the various participating centers to set up a biological collection for the collection and storage of sputum and stools of patients during the first year of treatment with elexacaftor\u002Ftezacaftor\u002Fivacaftor, in order to study the effect of treatment on the lung and digestive microbiota\u002Fmycobiota and inflammation.",[213],"Cystic Fibrosis",[215,216],"elexacaftor\u002Ftezacaftor\u002Fivacaftor","lung and digestive microbiota and inflammation",{"date":101,"type":39},{"date":219,"type":39},"2021-09-13",{"date":221,"type":21},"2026-09-13",{"name":45,"class":46},15,{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":240,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":257},"100548793","combined-platelet-and-erythrocyte-autotransfusion-during-cardiac-surgery-coltrane-trial-100548793","NCT06425614","COmbined pLaTelet and eRythrocyte AutotransfusioN During Cardiac surgEry (COLTRANE) Trial","Centrifugation-based Versus Filtration-based Intraoperative Cell Salvage on Quality of Perioperative Haemostasis in Cardiac Surgery: A Randomized Clinical Trial","COLTRANE","Inclusion Criteria:\n\nAdult patients (≥18 yr) affiliated or beneficiary of a social security scheme and undergoing on-pump cardiac surgery at high risk for bleeding with autotranfusion indication defined as:\n\n* Primary or redo combined cardiac procedures (2 valves or more, valve(s) and coronary artery bypass grafting(s))\n* Primary or redo ascending aorta surgery\n* Primary or redo isolated coronary artery bypass grafting (iCABG) involving 3 or more grafts using the internal mammary artery\n* Free, informed and written consent signed by the participant and the investigator\n\nExclusion Criteria:\n\n* Preoperative therapy by P2Y12 receptor inhibitors (within 5 preoperative days for clopidogrel, ticagrelor or ticlopidine, within 7 preoperative days for prasugrel, and within one preoperative hour for cangrelor)\n* Preoperative treatment by active anticoagulant drug (within 5 preoperative days for VKA, 4 days for dabigatran, 3 days for rivaroxaban and apixaban, 24 hours for therapeutic LMWH, 36 hours for therapeutic fondaparinux, 12 hours for prophylactic LMWH, 24 hours for prophylactic fondaparinux, 4 hours for unfractionated heparin Sepsis\n* Malignant tumor\n* Immunocompromised patients (steroids, immunosuppressive drugs, ongoing treatment for solid tumor or hematologic malignancy, primary immunodeficiency disorders, AIDS)\n* Emergency cardiac surgery\n* Heart transplantation\n* Implantation or patients under ventricular assist device (VAD)\n* Patients with two or more previous sternotomy\n* Surgery procedure requiring circulatory arrest and\u002For profound hypothermia (\\\u003C32°C)\n* Active infective endocarditis\n* Cardiac surgical procedure for benign or malignant cardiac tumors\n* Patients with known acquired or constitutional coagulopathy requiring specialist management\n* End stage renal disease\n* Preoperative haemoglobin level less than 10 g\u002FdL\n* Preoperative platelet count \\\u003C 100 G\u002FL\n* Persons participating in another interventional research including a period of exclusion that is still ongoing\n* Pregnant or breastfeeding women\n* Persons placed under judicial protection\n* Patients deprived of liberty",{"count":233,"type":21},570,[24],"Despite significant advances in patient blood management, cardiac surgery remains a surgical procedure at high risk for bleeding. Numerous perioperative blood conservation strategies have been developed for limiting the use of blood products. Among them, the processing of shed blood and residual cardiopulmonary bypass circuit volume with autotransfusion device is routinely used. Conventional centrifugation-based autotransfusion devices actually available only recover red blood cells while platelets and coagulation factors are almost totally lost. Consequently, large amounts of intraoperative cell salvage could significantly alter perioperative haemostasis. The SAME autotransfusion device (i-SEP, France) is a new and innovative filtration-based autotransfusion device able to recover erythrocytes, leukocytes but also platelets. By offering the opportunity to re-infuse to patients their own platelets in addition red blood cells, significantly improve perioperative haemostasis with this new device is expected. The purpose of the COLTRANE trial is to compare the quality of the perioperative haemostasis in cardiac surgical patients for whom intraoperative cell salvage will be performed using either the SAME autotransfusion device or conventional centrifugation-based device.\n\nBecause allogenic transfusion of blood products as well as surgical re-exploration for excessive bleeding are associated with poor outcomes and prolonged length of stay, the use of filtration-based SAME device by maintaining perioperative haemostasis could improve outcomes and reduce length of stay of high risk patients. The fact that patients receive their own platelets should also limit the risk of allo-immunization and immunomodulation which is recognized as one of the underlying mechanisms of perioperative increased risk of infection.",[237,238,239],"On-pump Cardiac Surgery","High Risk for Bleeding","Autotransfusion",[241,242,243,244,245,246,247,248],"cardiac surgery","bleeding","autotransfusion","cardiopulmonary bypass","perioperative haemostasis","Universal Definition of Perioperative Bleeding","filtration-based autotransfusion","centrifugation-based autotransfusion","2026-06-09",{"date":251,"type":39},"2026-06-11",{"date":253,"type":39},"2024-07-15",{"date":255,"type":21},"2027-02-15",{"name":45,"class":46},10,{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":18,"enrollmentInfo":265,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":47},"100362412","phase-3-in-vivo-involvement-of-the-cholinergic-and-dopaminergic-systems-in-the-pathophysiology-of-apathy-100362412","NCT03998852","In Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy.","ADACHOL","Inclusion Criteria:\n\n* Patient of legal age and younger than 75 years\n* Patient with a Rankin score less then or equal to 2 and with or without apathy, demonstrated by AI scales at 3 months after stroke (apathetic patient = AI scale score \\> 2)\n* Affiliate or beneficiary of a social security scheme\n* Subjects (female study subjects and female partners of male participants) using highly effective contraceptive methods (intra-uterine device, progestin or estrogen-progestin contraceptive, sterilization)\n* Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research)\n\nExclusion Criteria:\n\n* Patients over 75 years old\n* Taking of any pharmacological treatment likely to affect cholinergic systems at the time of PET-scan: Amitriptyline, Atropine, Brompheniramine, Chlorphenamine, Chlorpromazine, Clomipramine, Clozapine, Dimenhydrinate, Diphenhydramine, Doxepine, Hyoscyamine, Imipramine, Meclozine, Nortriptyline, Oxybutynine, Promethazine, Scopolamine, Trimipramine, Hydroxyzine.\n* Taking of any pharmacological treatment likely to affect dopaminergic systems at the time of PET-scan: glucagon, haloperidol, reserpin\n* Taking of any selective serotonine reuptake inhibitors treatment\n* White matter T2 hyperintense lesions (Fazekas score \\> 3)\n* NYHA Class III to IV Heart Failure Patient\n* Patients with allergy or conter-indication to entacapone\n* Subjects with positive pregnancy test (BHCG dosage and Urine dipstick), and\u002For currently breast-feeding\n* Patients unable to come back to hospital for at least 2-follow-up visits\n* Patient with a chronic neurological disorder or severe psychiatric disorder\n* Patient with cognitive impairment (MoCA\\\u003C24) and depression (CES-D score \\> 17 for men and \\>23 for women)\n* Patient presenting a counter-indication for MRI\n* Patient presenting a counter-indication for TEP with \\[18F\\]-FEOBV or \\[18F\\]-FDOPA (known allergy)\n* Patient who underwent a PET examination in the previous month\n* Patient with state of health not allowing a displacement in the department of imaging of the CHU: bedridden state, state of health very deteriorated\n* Patient deprived of liberty by judicial or administrative decision\n* Patient under legal protection or unable to express its own consent\n* Subject within exclusion period from another clinical trial",{"count":186,"type":21},[267],"PHASE3","Apathy is a neurocognitive syndrome characterized by reduced goal-directed behaviors, contributing to decreased patient and caregiver quality of life. Apathy pathophysiology involves disruption of cortico-striato-thalamo-cortical loops, modulated by several neurotransmitter systems including dopamine and acetylcholine, thus complexifying pharmacological management. Post-stroke apathy (PSA) can provide a proper in vivo model to study the underlying neurochemical substrates of apathy as a syndrome. The present project aims to provide a better characterization of the cholinergic and dopaminergic functioning in apathy as a syndrome.\n\nIn order to precise the respective alterations of these two systems, investigators will use a positron emission tomography (PET) molecular imaging of dopaminergic (with \\[18F\\]-FDOPA, a marker of the decarboxylating enzyme of dopamine) and - for the first time in apathetic patients - cholinergic (with \\[18F\\]-FEOBV, a marker of the vesicular acetylcholine transporter) transmissions in 15 apathetic and 15 unapathetic patients 3 months after stroke, without overlapping depression. This dual imaging study may provide help in guiding therapeutic management of PSA. The functional network analysis allowed by functional MRI is crucial to complement regional neurotransmitter deficits observed with PET. Altogether, a multimodal approach in apathy, combining PET and MRI, can allow identifying which circuits of the cortico-striato-thalamo-cortical loops are disrupted and how these circuits are modulated by other neurotransmitters.",[270],"Apathy",[270,272,273,274],"Stroke","Cholinergic neurotransmission","Dopaminergic neurotransmission",{"date":276,"type":39},"2026-06-10",{"date":278,"type":39},"2021-04-13",{"date":280,"type":21},"2027-05-13",{"name":45,"class":46},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":22,"phases":291,"briefSummary":293,"conditions":294,"keywords":299,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":81},"100423656","phase-4-antiplatelet-therapy-strategy-following-left-atrial-appendage-closure-100423656","NCT04796714","AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE","APPENDAGE","Inclusion Criteria:\n\n* Male or female patients with LAAC indication according to \"Commission nationale d'évaluation des dispositifs médicaux et des technologies de santé\" (CNEDiMTS) (National Commission for the Evaluation of Medical Devices and Health Technologies) guidelines\n* Age ≥ 18 years\n* Written informed consent provided by the patient\n* Heart team approval: multidisciplinary team including interventional cardiologists, neurologists and other physicians discussing the definitive contraindication for anticoagulation\n* Registration under social security system\n\nExclusion Criteria:\n\n* Minors\n* Unacceptable bleeding risk with double antiplatelet therapy decided by the physician who contraindicated oral anticoagulation\n* LAAC contraindication : left appendage thrombus\n* Major disease resulting in a life expectancy of \\\u003C 1 year\n* Severe and inherited bleeding disorder\n* Known hypersensitivity to aspirin and\u002For clopidogrel:\n\n  * Hypersensitivity to clopidogrel, acetylsalicylic acid, or one of the excipients or other nonsteroidal anti-inflammatory drugs (cross-reaction).\n  * Asthma or a history of asthma with or without nasal polyps induced by salicylates or substances of close activity, including nonsteroidal anti-inflammatory drugs.\n  * Evolving peptic ulcer or history of gastric hemorrhage or perforation after treatment with acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs.\n  * Any constitutional or acquired haemorrhagic disease.\n  * Patients with mastocytosis, in whom the use of acetylsalicylic acid can lead to severe hypersensitivity reactions (including circulatory shocks with flushing, hypotension, tachycardia and vomiting).\n  * Severe liver failure.\n  * Severe kidney failure (Creatinine light \\\u003C 30ml\u002Fmin).\n  * Uncontrolled severe heart failure\n* Contraindication to MRI: claustrophobia or inability to lie still for exam time, implantable pacemaker or defibrillator, intracorporeal metal foreign body (especially intraocular), intracranial metal clip, cochlear implant, cardiac valve prosthesis type Starr-Edwards pre 6000, or biomedical device type insulin pump or neurostimulator.\n* Guardianship\n* Curatorship\n* Pregnancy or child-bearing potential female\n* Woman of childbearing age who does not benefit from highly effective contraception (CTFG recommendation on highly effective contraceptive methods: oral, intravaginal or transdermal estrogeno-progestin contraception; progestin-based oral, injectable or implantable contraception; intrauterine device; hormonal intrauterine device; female sterilization (occlusion of the fallopian tubes))\n* Iode contraindication\n* Patient already participating in another category 1 interventional research\n* Patient in a period of exclusion relative to another research protocol.",{"count":290,"type":21},60,[292],"PHASE4","The APPENDAGE study is a phase 4 multicentre randomized opened clinical trial comparing 2 different antithrombotic strategies following left atrial appendage closure (LAAC) in patients with non valvular atrial fibrillation (AF). The primary objective of the study is to evaluate the efficacy of Aspirin versus Aspirin + Clopidogrel after LAAC by comparing the occurrence of ischemic lesions on cerebrovascular magnetic resonance imaging (MRI) studies.",[295,296,297,272,298],"Atrial Fibrillation","Atrial Appendage","Anticoagulants","Platelet Aggregation Inhibitors",[300,301,302,303,304],"left atrial appendage","percutaneous closure","stroke","antiplatelet therapy","atrial fibrillation","2026-06-08",{"date":276,"type":39},{"date":308,"type":39},"2022-10-03",{"date":310,"type":21},"2027-05-03",{"name":45,"class":46},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":320,"minAge":321,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":327,"conditions":328,"keywords":330,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":47},"100402904","phase-2-early-oxybutinin-treatment-for-boys-with-posterior-urethral-valves-100402904","NCT04526353","Early Oxybutinin Treatment for Boys With Posterior Urethral Valves","Prospective Randomized Clinical Trial of Early Oxybutinin Treatment for Boys With Posterior Urethral Valves","PRETIPUV","Inclusion Criteria:\n\n* Boys\n* Aged 3 to 6 months\n* Diagnosed with posterior urethral valves, and having undergone valve resection within the first 3 months of life\n* Children who have had their valve resection at least 3 months before inclusion\n* Having undergone urodynamic studies between 10 weeks and 6 months of age andshowing abnormal urodynamics, notably: high voiding pressure (\\>60cm H2O)\u002F small capacity bladder (\\\u003C70% expected bladder volume)and for those without pop-off mechanisms, poor compliance (\\\u003C10ml\u002FcmH2O)\u002F\n* Holders of parental authority affiliated to French national health insurance\n* With informed consent signed by holders of parental authority\n\nExclusion Criteria:\n\n* Boys with posterior urethral valves and normal urodynamics or no urodynamic assessment\n* Boys in whom urodynamic assessment is not possible for medical or anatomical reasons\n* Boys requiring dialysis before the age of 3 months\n* Contra-indication to oxybutynin such as hypersensitivity to oxybutynin or any of the excipients, digestive obstruction, occlusive or sub-occlusive syndrome, megacolon, digestive stasis, intestinal atony, paralytic ileus, ulcerative colitis, Hemorrhagic rectocolitis, Crohn's disease, Inflammatory bowel disease, Inflammatory organic colopathy, myasthenia, congenital glaucoma","MALE","3 Months","6 Months",{"count":324,"type":21},50,[326],"PHASE2","Boys with posterior urethral valves have bladder dysfunction of varying severity. Early treatment of these children with anticholinergics is recommended by some teams, although there have never been any clear studies on the subject. To our knowledge, no comparative study of the evolution of valve bladders with or without treatment has been carried out to date.\n\nAnticholinergic treatment, although it may be beneficial in patients with abnormal bladder function, such as the neurologic bladders ( in Spina Bifida) for example, may have side effects and may not be of benefit for this valve population. The evolution of the valves could be spontaneously favorable.\n\nThis study would be the first randomized clinical trial of early therapeutic drug intervention in the posterior urethral valve population.",[329],"Male Urogenital Diseases",[331,332,333],"posterior urethral valves","urodynamic","anticholinergic",{"date":276,"type":39},{"date":336,"type":39},"2020-09-10",{"date":338,"type":21},"2028-09-10",{"name":45,"class":46},{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":350,"briefSummary":351,"conditions":352,"keywords":354,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":47},"100622904","management-of-bone-loss-in-orthopaedic-surgery-using-the-masquelet-technique-or-transport-nails-100622904","NCT07389681","Management of Bone Loss in Orthopaedic Surgery Using the Masquelet Technique or Transport Nails","Evaluation of the Management of Bone Loss in Orthopaedic Surgery Using the Masquelet Technique or Transport Nails","EPSOCOT","Inclusion Criteria:\n\n* Patient ≥ 18 years\n* Minor patient, able to consent to data collection, with the consent of the owner(s)\n* Patient consulting for a medical reason involving a loss of bone substance in the lower limb in an investigating centre linked to one of these aetiologies for which a reconstruction procedure using a transport nail or Masquelet technique is envisaged:\n\n  * Tumour pathologies requiring\n  * Septic or aseptic pseudarthrosis\n  * Traumatic pathology\n  * Infectious pathologies\n\nExclusion Criteria:\n\n* Patients under guardianship or curatorship,\n* Individuals deprived of their liberty by judicial or administrative decision,\n* Individuals receiving involuntary psychiatric care requiring the consent of their legal representative,\n* Individuals unable to express their consent,\n* Individuals under legal protection,\n* Patients with an indication for bone reconstruction using a technique other than the Masquelet technique and nail transport,\n* Patients not covered by a social security scheme,\n* Patients ineligible for bone reconstruction due to their comorbidities",{"count":349,"type":21},250,[24],"This is a single-center prospective observational study comparing two techniques for reconstructing bone loss in the lower limbs. The aim of the study was to compare the results of reconstructions using the Masquelet technique with reconstructions using electromagnetic transport nails. The primary endpoint was time to bone healing. This study is the first prospective descriptive study of electromagnetic transport nails.",[353],"Critical-size Bone Defect",[355,356,357,358,359],"Bone transport","Critical-size bone defects","Distraction osteogenesis","Induced-membrane technique","Masquelet technique","2026-06-04",{"date":362,"type":39},"2026-06-05",{"date":364,"type":39},"2026-04-27",{"date":366,"type":21},"2034-03",{"name":45,"class":46},{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":376,"minAge":58,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":22,"phases":380,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":395},"100602072","dispensing-of-antibiotics-in-pharmacies-for-cystitis-according-to-a-delegation-protocol-impact-of-a-decision-support-tool-pharibo-pharmacy-and-resolved-antibiotherapy-for-urinary-tract-infections-100602072","NCT07118748","Dispensing of Antibiotics in Pharmacies for Cystitis According to a Delegation Protocol, Impact of a Decision Support Tool. PHARIBO: PHarmacy and Resolved Antibiotherapy for Urinary Tract Infections","Dispensing of Antibiotics in Pharmacies for Cystitis According to a Delegation Protocol, Impact of a Decision Support Tool : a Randomised Cluster Trial. PHARIBO: PHarmacy and Resolved Antibiotherapy for Urinary Tract Infections","PHARIBO","Inclusion Criteria:\n\n* woman,\n* symptom of acute cystitis without risk of complication,\n* affiliated to the french public welfare system,\n* signed consent.\n\nExclusion Criteria:\n\n* anomaly of the urinary canal,\n* pregnancy, more than 3 cystitis during the last year,\n* cancer,\n* immunosuppression,\n* hemopathy,\n* fever,\n* back-pain,\n* severe renal failure,\n* refuse to give consent and previously participate to the study,\n* under guardianship.","FEMALE","65 Years",{"count":379,"type":21},506,[24],"The purpose of this trial is to demonstrate that when treating acute cystitis without risk of complication, pharmacists may use share Decision Making tool to help patients to better understand the stakes of taking antibiotics and adapt the management of the delegation protocol.\n\nThis will select patients in need of antibiotics and preserve the full-capacities of non-treated one.",[383],"Acute Cystitis",[385,386,387,388],"cystitis","professional delegation","share decision making","antibiotics",{"date":305,"type":39},{"date":391,"type":39},"2026-05-19",{"date":393,"type":21},"2026-11",{"name":45,"class":46},14,{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":56,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":22,"phases":405,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":47},"100572571","identification-of-the-metabolic-signature-of-atrial-fibrillation-for-personalized-prevention-100572571","NCT06735001","Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention","IMAGE-AF","Inclusion Criteria:\n\n* Age ≥ 18 years, all genders, and ethnic origins\n* Free, informed, and written consent signed\n* Person affiliated to or benefiting from a social security scheme\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Lack of informed consent\n* Gestating women (pregnancy test carried out as part of care for FA patients, contraception, or menopause for women in control groups)\n* Persons under administrative or judicial protection\n* Endocarditis or pericarditis in progress or within the 3 last months\n* Active tumor pathology (benign or malignant)\n* Chronic inflammation or autoimmune disease\n* Chronic liver disease\n* Myocardial infarction within the last 8 weeks",{"count":404,"type":21},400,[24],"Atrial fibrillation (AF) is a major public health problem. The efficacy of the existing techniques is limited in the more aggressive forms. It is therefore necessary to develop approaches, in particular the identification of relevant biomarkers, to prevent the onset, recurrence or progression of AF in at-risk patients. The objective of this study is to describe the longitudinal metabolic and biomolecular signature of AF in patients eligible for cardiac ablation.",[408],"Atrial Fibrillation (AF)",[304,410,411,412],"prevention","biomarkers","cardiac metabolism",{"date":249,"type":39},{"date":415,"type":39},"2025-03-10",{"date":417,"type":21},"2029-10",{"name":45,"class":46},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":22,"phases":429,"briefSummary":430,"conditions":431,"keywords":436,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":47},"100640245","evaluation-of-the-evolution-of-patient-care-within-the-spinal-pathology-department-100640245","NCT07627282","Evaluation of the Evolution of Patient Care Within the Spinal Pathology Department","Evaluation of the Evolution of the Quality of Life of Patients Treated by the Spinal Pathology Department","SPINDATA","Inclusion criteria:\n\n* Patient \\> 18 years old\n* Minor patient, able to accept the data collection, with the consent of the holder(s)\n* Patient consulting for a medical reason involving a spinal pathology in the investigating center (spinal surgery department): Degenerative pathology of the thoracic or lumbar spine; Degenerative pathology of the cervical spine; Deformation of the spine; Urgent traumatic, infectious and tumor pathologies.\n\nExclusion criteria:\n\n* Patient under guardianship or curators,\n* Persons deprived of liberty by judicial or administrative decision,\n* Persons undergoing psychiatric treatment under duress requiring the consent of the legal representative\n* Persons unable to express their consent,\n* Persons under legal protection,\n* Patient not affiliated to a social protection scheme.",{"count":428,"type":21},15000,[24],"Spinal conditions are a major public health issue. Their management by surgical treatment is constantly improving and surgical procedures or implantable medical devices are experiencing significant progress. These innovations have not yet all been precisely evaluated but have already led to significant changes in care practices. The primary objective of our study is to describe, via an exhaustive collection of data, the quarterly evolution over 5 years of practices in the management of spinal pathologies.",[432,433,434,435],"Spinal Stenosis","SPINAL Fracture","Vertebral Osteomyelitis","Vertebral Metastasis",[437,438,439,440],"spine","care","surgery","evolution","2026-05-29",{"date":360,"type":39},{"date":444,"type":39},"2023-05-25",{"date":446,"type":21},"2031-08",{"name":45,"class":46},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":22,"phases":458,"briefSummary":459,"conditions":460,"keywords":464,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":47},"100423943","contribution-of-anti-platelet-antibodies-identified-with-maipa-assay-in-the-demonstration-of-the-auto-immune-character-of-a-thrombocytopenia-at-diagnosis-100423943","NCT04800458","Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis","Contribution of Anti-platelet Antibodies Identified With\" Monoclonal Antibody Immobilization of Platelet Antigens\" Assay (MAIPA) in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis","APAT","Inclusion Criteria:\n\n* Patient over 18 years old;\n* Patients with thrombocytopenia \\\u003C100 G\u002FL, checked twice, having ruled out false thrombocytopenia by platelet aggregation and acute leukemia by smear;\n* No treatment started;\n* Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any review required by the research);\n* Person affiliated or benefiting from a social security scheme.\n\nExclusion Criteria:\n\n* Secondary ITP;\n* False thrombocytopenia;\n* Patients who have been transfused with platelets for less than 7 days with efficacy;\n* Patient treated for thrombocytopenia (48 hours of corticosteroid therapy is tolerated and is not an exclusion criteria);\n* Patient with acute leukemia;\n* Pregnant or breastfeeding woman;\n* False thrombocytopenia;\n* Patient under guardianship, curatorship or any other legal protection regime.",{"count":457,"type":21},225,[24],"Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the disease or for its prognosis. ITP is a diagnosis of exclusion retained after elimination of other pathologies leading to a thrombocytopenia. No major study has prospectively evaluated the diagnostic value of the presence of anti-platelet antibodies in the etiological investigation of a thrombocytopenia, nor the impact of platelet antibodies on the course of ITP. The gold standard analysis for the determination of platelet antibodies, is the \"monoclonal antibody immobilization of platelet antigens\" assay (MAIPA), either direct to detect autoantibodies attached to platelets, or indirect to detect circulating antiplatelet antibodies. Therefore, this work aims to study the contribution of the presence of anti-platelet antibodies detected in MAIPA to determine the autoimmune nature of a thrombocytopenia at diagnosis.",[461,462,463],"Thrombocytopenia","Immune Thrombocytopenia","Myelodysplasia",[465,466,467,468],"Monoclonal antibody immobilization of platelet antigens assay","MAIPA","Anti-platelet antibodies","Thrombopoietin",{"date":470,"type":39},"2026-06-01",{"date":472,"type":39},"2021-05-19",{"date":474,"type":21},"2028-05",{"name":45,"class":46},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":22,"phases":485,"briefSummary":486,"conditions":487,"keywords":488,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":47},"100613004","ferroptosis-role-in-the-pathophysiology-of-systemic-lupus-erythematosus-100613004","NCT07260942","Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus","FERROLUP","Inclusion Criteria:\n\n* age ≥ 18 years;\n* diagnosis of systemic lupus erythematosus;\n* being affiliated to health insurance, willing to participate and to sign informed consent;\n* control group : patients with a diagnosis of rheumatoid arthritis or an inflammatory bowel disease.\n\nExclusion Criteria:\n\n* pregnant or breastfeeding women;\n* patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).",{"count":484,"type":21},120,[24],"The study aims at defining the role of ferroptosis s in the physiopathology of systemic lupus erythematosus (SLE). Ferroptosis (phenomenon of cellular death regulated by iron) is a metabolic pathway potentially implicated in SLE with potential for the discovery of new therapeutic strategies.",[70],[489,490,491],"Systemic lupus erythematosus","ferroptosis","autoimmunity","2026-05-13",{"date":494,"type":39},"2026-05-18",{"date":496,"type":39},"2026-04-21",{"date":498,"type":21},"2029-04",{"name":45,"class":46},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":47},"100640085","evaluation-of-the-administration-of-artificial-nutrition-by-feeding-jejunostomy-during-neoadjuvant-treatment-on-postoperative-morbidity-in-the-context-of-esophageal-or-stomach-cancer-100640085","NCT07584577","Evaluation of the Administration of Artificial Nutrition by Feeding Jejunostomy During Neoadjuvant Treatment on Postoperative Morbidity in the Context of Esophageal or Stomach Cancer","FREJENO","Inclusion Criteria:\n\n* Patient undergoing surgery for esophageal cancer\n* Malnourished patient at the time of management\n* Receiving neoadjuvant treatment\n\nExclusion Criteria:\n\n* Patient not malnourished at the time of management\n* Patient who did not receive neoadjuvant treatment",{"count":508,"type":21},670,"Malnutrition is common at the time of diagnosis of esogastric cancers. However, there are no recommendations regarding preoperative nutritional support (type and duration) or on the impact of refeeding on postoperative morbidity and mortality.",[511,512,513,514],"Esophageal Cancer","Surgery Indication","Malnourished","Neoadjuvant Treatment","2026-05-07",{"date":492,"type":39},{"date":518,"type":21},"2026-11-01",{"date":520,"type":21},"2026-11-30",{"name":45,"class":46},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":22,"phases":531,"briefSummary":532,"conditions":533,"keywords":537,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":551,"locationsCount":552},"100623143","age-accumulation-in-patients-on-long-term-parenteral-nutrition-100623143","NCT07392801","AGE Accumulation in Patients on Long-term Parenteral Nutrition","Study of Advanced Glycation End-products Accumulation in Patients Under Long-Term Parenteral Nutrition (NUPARAGE2)","NUPARAGE2","Inclusion Criteria:\n\n* Patients (adults and children, all ages) initiating long-term parenteral nutrition\n* Followed at CHU de Bordeaux or Robert Debré Hospital (APHP)\n* Covered by French Social Security system\n* Written informed consent obtained from patient (if adult) or legal guardian (if minor)\n\nExclusion Criteria:\n\n* Fitzpatrick skin type ≥ V (darker skin tones)\n* Forearm tattoos at the site of measurement\n* For patients included under 1 year of age: patients born prematurely (before 37 weeks of amenorrhea)\n* Pregnant or breastfeeding women.",{"count":324,"type":21},[24],"This prospective and observational study aims to evaluate the accumulation of advanced glycation end-products (AGEs) in adult and pediatric patients starting long-term parenteral nutrition, by non-invasive skin AGE measurements over a 12-month follow-up.",[534,535,536],"Chronic Intestinal Insufficiency","Advanced Glycation and Products","Parenteral Nutrition",[538,539,540,541,542,543,544],"parenteral nutrition","Advanced Glycation End Products","Oxidative Stress","Metabolic Diseases","Cardiovascular Diseases","Short Bowel Syndrome","chronic intestinal insufficiency","2026-04-30",{"date":547,"type":39},"2026-05-06",{"date":549,"type":21},"2026-05",{"date":474,"type":21},{"name":45,"class":46},3,{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":22,"phases":562,"briefSummary":563,"conditions":564,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":569,"completionDateStruct":570,"leadSponsor":572,"locationsCount":47},"100629734","phase-2-fapi-pet-value-for-the-initial-screening-of-pancreatic-and-biliary-cancers-100629734","NCT07478523","FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers","Diagnostic Value of 68Ga-FAPI-46 PET\u002FCT in the Initial Work-up of Pancreatic and Biliary Cancers Eligible to a Curative Treatment","FAPDIG","Inclusion Criteria:\n\n* Population 1: De novo pancreatic adenocarcinoma (pathological evidence) or strong suspicion of de novo pancreatic adenocarcinoma on imaging, immediately resectable, borderline or locally advanced, potentially requiring curative treatment and non-metastatic (M0), according to reference staging. - Population 2: De novo cholangiocarcinoma eligible for curative treatment (pathological evidence) or strong suspicion of de novo pancreatic adenocarcinoma on imaging, non-metastatic (M0), according to reference extension assessment. according to reference extension report\n\nCriteria common to both populations:\n\n* Age \\>18 years at the time of signing the informed consent\n* Patient affiliated to a social security system\n* Free and informed consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research)\n\nExclusion Criteria:\n\n* Tumor M+ or with suspicion of distant metastasis on standard staging.\n* Neoadjuvant treatment\n* History of other active cancer\n* Pregnant or breastfeeding woman\n* Person under legal protection (guardianship or curatorship)\n* Person unable to personally give consent\n* Person in an emergency situation\n* Exclusion period from another protocol\n* Person deprived of liberty by judicial or administrative decision",{"count":484,"type":21},[326],"Pancreatic cancer is one of the worst-prognosed cancers with a 5-year survival rate of less than 10%. Its incidence has been steadily increasing for several years in France and worldwide. Pancreatic adenocarcinoma may become the second leading cause of cancer mortality in the years 2030-2040. Current standard of care for pancreatic cancer imaging at initial workup comprise CT imaging and MRI. However, these imaging modalities lack sensitivity and accuracy, with an estimated rate of about 30% of patients either with visceral or lymph node metastasis discovered during planned surgery or with relapse occurring during the first 6 months after surgery suggesting occult metastasis at diagnosis. Therefore, there is a clear need for new imaging modalities at initial diagnosis for more adapted and individualized therapeutic decision.\n\nCholangiocarcinoma (or cancer of the bile ducts) also has a dismal prognosis with a 5-year survival rate of 7%. The therapeutic objective is to obtain a surgical resection R0 when possible which can be associated with improved survival of up to 40% in appropriately selected patients. However, surgical morbidity and mortality are high, especially in peri-hilar forms. The detection of lymph node metastasis beyond the hepatic hilum is crucial, as surgery is considered futile in this situation. Current standard imaging at initial work-up include CT and MRI that have limited performance in estimating surgical resecability with a sensitivity of 60% for detecting lymph nodes metastasis and 67% for detecting distant metastasis. Therefore, there is also here an unmet need for improved baseline imaging.\n\nIn summary, this project is focused on two digestive cancers with poor prognosis in which preoperative imaging accuracy remains today imperfect.\n\nTherefore, we aim to demonstrate, when compared with current standard imaging, that 68Ga-FAPI-46 PET\u002FCT performed at baseline imaging in pancreatic and biliary duct cancers, leads to a change in TNM classification and subsequently to a change in therapeutic management.\n\nTo our knowledge, this will be the first (or one of the first) structured multicenter prospective study to evaluate the additional and potentially decisive contribution of 68Ga-FAPI-46 PET\u002FCT carried out after a standard imaging workup at initial diagnosis of pancreatic and biliary duct cancers.\n\nIf the diagnostic superiority of 68Ga-FAPI-46 PET\u002FCT is confirmed, this study could lead to define a new standard of care for the imaging of these cancers with poor prognosis. The study should also help to set the ground for future theranostic approaches where 68Ga-FAPI-46 PET\u002FCT would help select patients for targeted radionuclide therapy.",[565,566],"Cholangiocarcinoma","Pancreatic Adenocarcinoma","2026-04-24",{"date":545,"type":39},{"date":496,"type":39},{"date":571,"type":21},"2029-03-21",{"name":45,"class":46},{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":579,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":376,"minAge":58,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":22,"phases":582,"briefSummary":583,"conditions":584,"keywords":589,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":602,"leadSponsor":604,"locationsCount":47},"100634631","pre-anesthetic-teleconsultations-during-pregnancy-100634631","NCT07542197","Pre-anesthetic Teleconsultations During Pregnancy","ECO-CAM: Pre-anesthetic Consultations During Pregnancy: Benefits of Teleconsultation for Patient Assessment, Information, and Ecological Impact","ECO-CAM","Inclusion Criteria:\n\n* Pregnant patients scheduled to give birth at the Bordeaux University Hospital, ASA score 1 or 2, for their primary pregnancy, who have booked an anesthesia appointment on one of the half-days when teleconsultation is available in the department\n* Have access to the internet and functional computer equipment (smartphone, computer)\n* Have a valid email address and telephone number\n\nExclusion Criteria:\n\n* Minor patient (under 18 years old at the time of inclusion)\n* Individuals not affiliated with or beneficiaries of a social security scheme\n* Patients who do not speak French\n* Persons under legal guardianship\n* Psychiatric conditions that impair the ability to consent to or participate in the study\n* Severe spinal pathology (scoliosis requiring a brace or surgery, ankylosing spondylitis), history of spinal surgery\n* Comorbidities with ASA score ≥3",{"count":349,"type":21},[24],"Quality of teleconsultation in comparison to face-to-face consultation for pre anesthetic evaluation in pregnant persons before delivery will be evaluated. Quality is evaluated with a composite criterion comprising 7 elements required for security of anesthesia. Discordance between this composite criterion during the pre anesthesia visit the day of delivery and pre anesthesia consultation several weeks before delivery will be assessed.",[585,586,587,588],"Pregnancy","Anesthesia","Satisfaction","Telemedicine",[590,591,592,593,594,595,596,597],"pre anesthetic consultation","anesthesia","obstetrics","carbon footprint","e-health","electronic medical records","telehealth","telemedicine","2026-04-22",{"date":600,"type":39},"2026-04-28",{"date":38,"type":21},{"date":603,"type":21},"2028-06",{"name":45,"class":46},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":611,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":320,"minAge":613,"maxAge":4,"enrollmentInfo":614,"targetDuration":4,"studyType":22,"phases":616,"briefSummary":617,"conditions":618,"keywords":625,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":633,"leadSponsor":635,"locationsCount":636},"100635690","comparing-clean-intermittent-self-catheterization-and-indwelling-catheterization-for-the-management-of-urinary-retention-before-bph-surgery-100635690","NCT07555964","Comparing Clean Intermittent Self-catheterization and Indwelling Catheterization for the Management of Urinary Retention Before BPH Surgery.","Comparing Clean Intermittent Self-catheterization and Indwelling Catheterization for the Management of Urinary Retention Before BPH Surgery.l","CATHETERS","Inclusion Criteria:\n\n* Men over 50 years old;\n* Confirmed diagnosis of benign prostatic hyperplasia (BPH);\n* Prostate volume greater than 40 grams;\n* Presence of acute urinary retention with failure to wean from the catheter despite medical treatment with alpha-blocker for at least 48 hours\n* Indication for surgical management of BPH;\n* Patient affiliated with or a beneficiary of a social security scheme;\n* Signed informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Patient with a history of prostate surgery (including BPH surgery), prostatic artery embolization or Urolift implant placement are not considered a history of prostate surgery;\n* Patient with symptomatic urethral stricture;\n* Patient with a bladder emptying disorder of neurogenic origin;\n* Patient with an anatomical contraindication to ICSC (urethral stricture, false urethral route);\n* Patient who had urine drainage by suprapubic catheter\n* Patient with motor, neurological, anatomical, or cognitive difficulties preventing the education or learning of ICSC;\n* Patient contraindicated for surgical management of their BPH;\n* Patient unable to understand the research documents and provide informed consent;\n* Persons subject to legal protection measures or placed under judicial protection.","50 Years",{"count":615,"type":21},106,[24],"The CATHETERS trial is a multicenter, randomized, open-label superiority study comparing two methods of managing urinary retention before surgery for benign prostatic hyperplasia (BPH): clean intermittent self-catheterization (ICSC) versus indwelling catheter (IDC). The primary objective is to determine whether ICSC reduces the occurrence of infectious complications (urinary bacterial colonization requiring antibiotic therapy, urinary tract infection, or urosepsis) compared to IDC in men awaiting BPH surgery. A total of 106 patients will be enrolled across multiple centers in France, with follow-up extending to three months after surgery.",[619,620,621,622,623,624],"Prostatic Hyperplasia","Urinary Retention","Urinary Catheterization","Intermittent Urethral Catheterization","Urinary Tract Infections","Surgical Procedures",[626,627,628,629],"BPH","ICSC","IDC","Urinary Tractus Infection",{"date":631,"type":39},"2026-04-29",{"date":567,"type":21},{"date":634,"type":21},"2028-04-24",{"name":45,"class":46},5,{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":641,"acronym":642,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":22,"phases":646,"briefSummary":647,"conditions":648,"keywords":651,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":655,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":47},"100622730","ultradian-steroid-rhythms-in-adrenal-incidentalomas-100622730","NCT07387419","Ultradian Steroid Rhythms in Adrenal Incidentalomas","CHRONOMACS","Inclusion Criteria:\n\n* 18 \\\u003C Age ≤ 85 years.\n* Patient with one or more uni or bilateral adrenal nodules of cortical appearance on CT scan.\n* Subject affiliated or beneficiary of a social security scheme.\n\nThe diagnostic criteria are:\n\nFor the MACS group:\n\n* a serum cortisol concentration after a minute braking test with dexamethasone \\> 50 nmol\u002FL or 1.8 µg\u002FdL, with a concomitant dexamethasone concentration above the test validation threshold\n* morning plasma ACTH concentration ≤ 2.5 pmol\u002FL or 11 pg\u002FmL.\n\nFor the non-secreting adenoma group:\n\n\\- Plasma cortisol after minute dexamethasone braking test ≤ 50 nmol\u002FL or 1.8 µg\u002FdL.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnant or breast-feeding\n* Use of oral estrogens (must be discontinued for at least 6 weeks prior to sampling)\n* Known adrenal insufficiency and\u002For treatment with steroids (oral, inhaled, parenteral or topical) or other interfering drugs.\n* patient taking part in another study\n* Patients placed under legal protection measures and\u002For deprived of their liberty",{"count":645,"type":21},40,[24],"Twenty to 40% of adrenal incidentalomas are responsible for MACS (mild autonomous cortisol producing secretion). The biological tools used in current practice to explore MACS do not provide precise information on cortisol production abnormalities. This study is a comparative analysis of the dynamics\u002Frhythmicity of interstitial cortisol and other steroid concentrations between MACS and non-secreting adenomas (ANS). Using the original and innovative U-RHYTHM system, interstitial fluid samples will be taken every 20 minutes for 24 to 48 hours from patients with MACS or non-secreting adenomas, and steroid assays will be performed in the perfusates to analyze steroid hormone production over 24 hours.",[649,650],"Mild Autonomous Cortisol Secretion Adenoma","Non Secreting Adenoma",[652,653,654],"Adrenal incidentaloma","Mild autonomous cortisol secretion adenoma","Ultradian steroid rhythms","2026-04-20",{"date":657,"type":39},"2026-04-23",{"date":659,"type":39},"2026-04-15",{"date":661,"type":21},"2027-10",{"name":45,"class":46},{"id":664,"slug":665,"hasResults":12,"nctId":666,"briefTitle":667,"officialTitle":668,"acronym":669,"eligibilityCriteria":670,"healthyVolunteers":12,"sex":376,"minAge":671,"maxAge":613,"enrollmentInfo":672,"targetDuration":4,"studyType":22,"phases":674,"briefSummary":675,"conditions":676,"keywords":678,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":684,"lastUpdatePostDateStruct":685,"startDateStruct":686,"completionDateStruct":687,"leadSponsor":689,"locationsCount":690},"100607957","radiofrequency-endometrial-ablation-or-uterine-artery-embolization-for-treatment-of-adenomyosis-related-abnormal-uterine-bleeding-100607957","NCT07195305","Radiofrequency Endometrial Ablation or Uterine Artery Embolization for Treatment of Adenomyosis-related Abnormal Uterine Bleeding","Radiofrequency Endometrial Ablation or Uterine Artery Embolization for Women With Adenomyosis-related Abnormal Uterine Bleeding Eligible for Hysterectomy: a Non-inferiority Randomized Clinical Trial Comparing Each Intervention to Hysterectomy","ADENOTREAT","Inclusion Criteria:\n\n* Premenopausal women aged 30 to 50 years\n* Women who had at least 3 prior months failed medical therapy, or a contraindication to medical therapy, or refused medical therapy for adenomyosis-related AUB\n* Symptomatic pure internal adenomyosis or dominant adenomyosis (with less than 5 concurrent uterine fibroids type 3-7 \\\u003C 5 cm) confirmed by MRI (\\\u003C 6 months) according to ESHRE criteria\n* AUB defined as a PBAC score \\>100 at baseline\n* Uterine ultrasound measurement of 6.0-12.0 cm (external os to internal fundus)\n* Women with an indication for hysterectomy for adenomyosis-related AUB and accepting hysterectomy\n* Highly effective contraception for women of childbearing potential, maintained until the onset of menopause\n* Affiliated or beneficiary of health insurance\n* Signed informed consent\n\nExclusion Criteria:\n\n* Uterine cavity abnormality or obstruction confirmed via imaging modalities or hysteroscopy\n* Deep infiltrating posterior subperitoneal endometriosis involving contiguous digestive tract structures\n* Uterine malignancy within the last five years\n* Secreting ovarian tumor\n* Atypical endometrial hyperplasia\n* Unaddressed high grade cervical intra-epithelial lesions\n* Active sexually transmitted disease or pelvic inflammatory disease\n* Documented or suspected coagulopathies or long-term blood-thinner medications\n* Prior transmural myomectomy or prior endometrial ablation\n* Plasma FSH level \\> 40 IU\u002FmL\n* Any contraindication to angiography (including iodine allergy and creatinine clearance \\\u003C 60mL\u002Fmin)\n* Any contraindication to MRI (claustrophobia, pace maker, etc.)\n* Any contraindication to the use of Embosphere®, Embozene® or NovaSure® according to the instruction for use\n* Women who are pregnant, breastfeeding, or who are planning to become pregnant\n* Any condition or any situation that would prohibit women from coming to the investigational center for the 6 months follow-up\n* Women unable to understand the nature, risks, significance and implications of the clinical investigation\n* Women under legal protection","30 Years",{"count":673,"type":21},230,[24],"The present study aims to compare the efficacy (menstrual blood loss, pain, quality of life) and the safety (complications, recovery) of each conservative intervention (RFA, UAE) versus hysterectomy for the treatment of adenomyosis-related abnormal uterine bleeding, up to 2 years",[677],"Abnormal Uterine Bleeding Due to Adenomyosis (Disorder)",[679,680,681,682,683],"Radiofrequency endometrial ablation","Uterine artery embolization","Hysterectomy","Adenomyosis","Abnormal uterine bleeding","2026-04-17",{"date":655,"type":39},{"date":684,"type":39},{"date":688,"type":21},"2029-05",{"name":45,"class":46},4,{"id":692,"slug":693,"hasResults":12,"nctId":694,"briefTitle":695,"officialTitle":696,"acronym":697,"eligibilityCriteria":698,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":699,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":701,"conditions":702,"keywords":704,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":709,"lastUpdatePostDateStruct":710,"startDateStruct":711,"completionDateStruct":713,"leadSponsor":715,"locationsCount":4},"100629117","pathophysiological-mechanisms-involved-in-the-pronostic-and-evolution-of-non-small-cell-lung-cancer-nsclc-at-all-stages-of-the-disease-100629117","NCT07470476","Pathophysiological Mechanisms Involved in the Pronostic and Evolution of Non-Small Cell Lung Cancer (NSCLC) at All Stages of the Disease","Progression of NSCLC at All Stages of the Disease - Pathophysiological Mechanisms - Innovative Approaches to Translational Biology","EMA","Inclusion Criteria:\n\n* Adult patients\n* NSCLC treated at the Bordeaux University Hospital.\n* TNM stage between I to IV\n* Patient affiliated with or beneficiary of a social security scheme.\n* Non opposition\n\nExclusion Criteria:\n\n* Patients with small cell lung cancer.\n* History of any other malignancy other than NSCLC within 1 years prior to screening. except for non-melanoma skin cancers, in situ cancers, or low-risk prostate cancer\n* Pregnant or breastfeeding women.\n* Patients with a medical or psychiatric condition or illness that compromises their ability to understand the information or participate in the study.\n* Individuals subject to legal protection measures (legal guardianship, trusteeship or curatorship).\n* Individuals deprived of their liberty by judicial or administrative decision.\n* Individuals who are unable to give their consent.\n* Patients who are in a period of exclusion following another study or who have participated in another interventional study involving a medicinal product within 30 days prior to entry into the protocol or who are participating in another clinical study.",{"count":700,"type":21},150,"This single-center observational cohort study conducted at Bordeaux University Hospital aims to establish a structured clinico-biological platform in non-small cell lung cancer (NSCLC) to investigate the biological mechanisms involved in tumor initiation, progression, and relapse across all disease stages (I-IV).\n\nA total of 150 consecutive adult patients with histologically or cytologically confirmed NSCLC will be included over a 3-year period. Tumor samples will undergo translational analyses. These biological data will be correlated with pseudonymized clinical data collected from medical records and the institutional clinical data warehouse.\n\nThe primary objective is to characterize the molecular, metabolic, and immune mechanisms associated with tumor progression and recurrence in NSCLC.\n\nThe central hypothesis is that integrating comprehensive clinical data with in-depth molecular and immunological analyses of tumor tissues will identify biologically distinct patterns associated with disease evolution, therapeutic resistance, and prognosis. Such integrated clinico-biological signatures may improve patient stratification and contribute to the identification of novel biomarkers and therapeutic targets in NSCLC.",[703],"Non Small Cell Lung Cancer",[705,706,707,708],"Non small-cell lung cancer","Pathophysiology","Prognosis","Innovative therapies","2026-04-14",{"date":684,"type":39},{"date":712,"type":21},"2026-06",{"date":714,"type":21},"2041-06",{"name":45,"class":46},""]